The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Conditional OK Might Be an Option for KM Biologics Jab: Komeito Lawmaker
Japan could look at the use of its conditional early approval system for an inactivated COVID-19 vaccine being developed by KM Biologics without waiting for the proposed introduction of an emergency clearance scheme, Komeito lawmaker Kozo Akino said on February…
To read the full story
Related Article
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
- KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023
November 11, 2022
- KD-414 Presumed to Have Superior Efficacy over Vaxzevria: KM Bio President
July 7, 2022
- 1st Dose of COVID-19 Jab Given in Adult and Pediatric Trials: KM Biologics/Meiji
May 10, 2022
- KM Biologics to Soon Begin Pediatric PII/III for COVID Jab, 1st Japan Trial to Include Kids below Age 5
April 21, 2022
- KM Biologics to File COVID-19 Vaccine as Early as September, Chancing Emergency Approval
April 21, 2022
- KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
- KM Biologics’ COVID-19 Jab Enters Japan PII/III Study
October 25, 2021
- KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022
September 22, 2021
- KM Biologics Kicks Off Japan PI/II for COVID-19 Vaccine
March 23, 2021
REGULATORY
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…